Priority Review Vouchers: Buyers Beware!
This article was originally published in RPM Report
The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.
You may also be interested in...
In an interview, CEO Cameron Durrant said the time was right for KaloBios to outline its pricing strategy as the company looks to emerge from the Martin Shkreli scandal and bankruptcy.
Marketing exclusivity may be better way to go, FDA tells GAO, citing workload burdens and lack of evidence that vouchers have incentivized development of new treatments.
House committee members deliver a fierce, if not terribly substantive, critique of FDA review processes as part of a hearing on Turing and Valeant.